Cardiology in Review article asks whether eloralintide’s early cardiometabolic effects could matter for heart risk
MechanismP1Primary public evidencePeer-reviewed publication
On 16 September 2026 Sigalov and Frishman published a literature review of early clinical studies of eloralintide and its cardiometabolic effects, including body weight, pulse rate, blood pressure, inflammatory markers and lipids. They note that no amylin receptor agonist, eloralintide included, has been tested in a dedicated cardiovascular outcomes trial.
Background and context
Who wrote it
Both authors are at New York Medical College School of Medicine in Valhalla, New York. The PubMed record lists no Lilly affiliation for either of them. It does not show funding or competing-interest statements, which sit in the full paper.
What the review sets out to do
The abstract describes a literature review of early clinical studies of eloralintide. It asks whether weight loss and the other cardiometabolic effects may be relevant to cardiovascular risk reduction. It singles out the fall in pulse rate, which it contrasts with the rise in heart rate it associates with GLP-1 receptor agonists. That contrast is drawn across separate studies and is not a head-to-head comparison.
Where it stops
The authors call their epidemiological benchmarks contextual, not predictive. Pulse rate, blood pressure and lipid readings are markers. They are not heart attacks or strokes, which only a dedicated outcomes trial can count.
Sigalov A, Frishman WH, Cardiology in Review, 2026, via PubMed (PMID 42745233). DOI 10.1097/CRD.0000000000001468.
